PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF VERINURAD (RDEA3170) IN ADULT MALE SUBJECTS WITH MILD, MODERATE, AND SEVERE RENAL IMPAIRMENT: A PHASE 1, OPEN-LABEL STUDY

被引：0
|
作者：
Smith, W. B. [1 ]
Hall, J. [2 ]
Berg, J. K. [3 ]
Kazimir, M. [3 ]
Yamamoto, A. [2 ]
Walker, S. [4 ]
Lee, C. [2 ]
Marbury, T. C. [5 ]
机构：
[1] Volunteer Res Grp, Knoxville, TN USA
[2] Ardea Biosci Inc, San Diego, CA USA
[3] DaVita Clin Res, Minneapolis, MN USA
[4] Astrazeneca, Gaithersburg, MD USA
[5] Orlando Clin Res Ctr, Orlando, FL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5327
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0433
引用
收藏
页码：371 / 371
页数：1
相关论文
共 50 条
  • [1] Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
    Smith, William B.
    Hall, Jesse
    Berg, Jolene
    Kazimir, Michal
    Yamamoto, Amy
    Lee, Caroline
    Walker, Susan
    Marbury, Thomas C.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] PHARMACODYNAMIC EFFECTS AND SAFETY OF VERINURAD (RDEA3170) IN COMBINATION WITH FEBUXOSTAT VERSUS FEBUXOSTAT ALONE IN ADULTS WITH GOUT: A PHASE 2A, OPEN-LABEL STUDY
    Fleischmann, R.
    Winkle, P.
    Hall, J.
    Valdez, S.
    Liu, S.
    Yan, X.
    Hicks, L.
    Hernandez-Illas, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 371 - 371
  • [3] PHARMACODYNAMIC EFFECTS AND SAFETY OF VERINURAD (RDEA3170) IN COMBINATION WITH ALLOPURINOL VERSUS ALLOPURINOL ALONE IN ADULTS WITH GOUT: A PHASE 2A, OPEN-LABEL STUDY
    Fleischmann, R.
    Winkle, P.
    Miner, J. N.
    Yan, X.
    Hicks, L.
    Valdez, S.
    Hall, J.
    Hernandez-Illas, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1364 - 1364
  • [4] PHARMACODYNAMICS, PHARMACOKINETICS, AND SAFETY OF VERINURAD (RDEA3170) IN COMBINATION WITH FEBUXOSTAT VERSUS FEBUXOSTAT ALONE AND VERINURAD ALONE IN JAPANESE ADULTS WITH GOUT OR ASYMPTOMATIC HYPERURICEMIA: A PHASE 2A, OPEN-LABEL STUDY
    Shiramoto, M.
    Liu, S.
    Shen, Z.
    Hall, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 371 - 372
  • [5] A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment
    Marbury, T.
    Stonerock, R.
    Acharya, M.
    Gonzalez, M.
    Jiao, J.
    Breeding, J.
    Haqq, C.
    Molina, A.
    Tran, N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S501 - S501
  • [6] An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment
    Nakamaru, Yoshinobu
    Kakubari, Masae
    Yoshida, Kaori
    Akimoto, Makoto
    Kondo, Kazuoki
    CLINICAL THERAPEUTICS, 2020, 42 (09) : 1699 - 1714
  • [7] A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
    Cheng, Yiming
    Ye, Ying
    Gaudy, Allison
    Ghosh, Atalanta
    Xue, Yongjun
    Wang, Alice
    Zhou, Simon
    Li, Yan
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2023, 15 : 9 - 19
  • [8] Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
    Fleischmann, Roy
    Winkle, Peter
    Miner, Jeffrey N.
    Yan, Xiaohong
    Hicks, Liz
    Valdez, Shakti
    Hall, Jesse
    Liu, Sha
    Shen, Zancong
    Gillen, Michael
    Hernandez-Illas, Martha
    RMD OPEN, 2018, 4 (01):
  • [9] Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
    Fleischmann, Roy
    Winkle, Peter
    Hall, Jesse
    Valdez, Shakti
    Liu, Sha
    Yan, Xiaohong
    Hicks, Liz
    Lee, Caroline
    Miner, Jeffrey N.
    Gillen, Michael
    Hernandez-Illas, Martha
    RMD OPEN, 2018, 4 (01):
  • [10] An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function
    Tomkinson, H. K.
    Weil, A.
    Engelhardt, E.
    Schmid, K.
    Oliver, S.
    Morris, T.
    Swaisland, H.
    Taboada, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 132 - 132
12345